These vesicles hydrolyze the ATP released by tumor cells into adenosine and subsequently inhibit the anti‐tumor response mediated by CD8+ T cells through these adenosines.[155] Therefore, HIF‐1α and Rab27A may be novel targets for the development of anti‐tumor drugs. This evidence concerns the gene HIF1A and neoplasm.